Related Experiment Videos
Second trimester abortion with prostaglandin F2 alpha
Summary
This clinical trial found that 50 mg of prostaglandin F2 alpha (PGF2 alpha) is effective for midtrimester abortion in nulliparous patients, while 40 mg suffices for multiparous women.
Area of Science:
- Reproductive Medicine
- Obstetrics and Gynecology
Background:
- Midtrimester abortion induction requires effective and safe pharmacological agents.
- Prostaglandin F2 alpha (PGF2 alpha) is a known agent for inducing labor and abortion.
Purpose of the Study:
- To compare the efficacy and safety of two intraamniotic doses of prostaglandin F2 alpha (PGF2 alpha) for midtrimester abortion.
- To determine optimal dosing of PGF2 alpha based on parity and gestational age.
Main Methods:
- A clinical trial involving 48 patients at 15-20 weeks' gestation.
- Patients received either a 40-mg (n=20) or 50-mg (n=28) intraamniotic dose of PGF2 alpha.
- Success rates, induction-to-abortion intervals, and side effects were recorded.
Main Results:
- Success rates were 85% for 40 mg and 93% for 50 mg of PGF2 alpha.
- All nulliparous patients receiving 50 mg and multiparous patients receiving 40 mg aborted within 48 hours.
- The 50-mg dose resulted in a mean induction-to-abortion interval two hours shorter than the 40-mg dose.
Conclusions:
- Intraamniotic 50 mg of PGF2 alpha is effective for midtrimester abortion in nulliparous women.
- A 40-mg dose of PGF2 alpha is sufficient for multiparous women.
- Gestational age did not impact the induction-to-abortion interval with the 50-mg dose.